These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 15870412)

  • 41. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Eur Urol; 2014 Jan; 65(1):177-85. PubMed ID: 22981136
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mortality of patients with clinically localized prostate cancer treated with observation for 10 years or longer: a population based registry study.
    Brasso K; Friis S; Juel K; Jørgensen T; Iversen P
    J Urol; 1999 Feb; 161(2):524-8. PubMed ID: 9915440
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men.
    van den Bergh RC; Roemeling S; Roobol MJ; Aus G; Hugosson J; Rannikko AS; Tammela TL; Bangma CH; Schröder FH
    BJU Int; 2009 Jun; 103(11):1472-7. PubMed ID: 19154509
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostate-specific antigen recurrence and mortality after conventional dose radiation therapy in select men with low-risk prostate cancer.
    Petit JH; Chen MH; Loffredo M; Sussman B; Renshaw AA; D'Amico AV
    Cancer; 2006 Nov; 107(9):2180-5. PubMed ID: 17009323
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection.
    Wattson DA; Chen MH; Moran BJ; Dosoretz DE; Braccioforte MH; Salenius SA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e773-9. PubMed ID: 22300573
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy).
    Tewari A; Raman JD; Chang P; Rao S; Divine G; Menon M
    Urology; 2006 Dec; 68(6):1268-74. PubMed ID: 17169648
    [TBL] [Abstract][Full Text] [Related]  

  • 48. How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden.
    Andrén O; Fall K; Franzén L; Andersson SO; Johansson JE; Rubin MA
    J Urol; 2006 Apr; 175(4):1337-40. PubMed ID: 16515993
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy.
    Tomioka A; Tanaka N; Yoshikawa M; Miyake M; Anai S; Chihara Y; Okajima E; Hirayama A; Hirao Y; Fujimoto K
    BMC Cancer; 2015 May; 15():420. PubMed ID: 25990314
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancer.
    Rosenberg JE; Chen MH; Nguyen PL; Braccioforte MH; Moran BJ; D'Amico AV
    Clin Genitourin Cancer; 2012 Mar; 10(1):21-5. PubMed ID: 22130293
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era.
    Carter CA; Donahue T; Sun L; Wu H; McLeod DG; Amling C; Lance R; Foley J; Sexton W; Kusuda L; Chung A; Soderdahl D; Jackmaan S; Moul JW
    J Clin Oncol; 2003 Nov; 21(21):4001-8. PubMed ID: 14581423
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High-Dose-Rate Monotherapy for Localized Prostate Cancer: 10-Year Results.
    Hauswald H; Kamrava MR; Fallon JM; Wang PC; Park SJ; Van T; Borja L; Steinberg ML; Demanes DJ
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):667-74. PubMed ID: 26443877
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term impact of conservative management on localized prostate cancer. A twenty-year experience in Japan.
    Egawa S; Go M; Kuwao S; Shoji K; Uchida T; Koshiba K
    Urology; 1993 Nov; 42(5):520-6; discussion 526-7. PubMed ID: 8236593
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Disease-specific survival following routine prostate cancer screening by digital rectal examination.
    Gerber GS; Thompson IM; Thisted R; Chodak GW
    JAMA; 1993 Jan; 269(1):61-4. PubMed ID: 8416407
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Questioning the 10-year Life Expectancy Rule for High-grade Prostate Cancer: Comparative Effectiveness of Aggressive vs Nonaggressive Treatment of High-grade Disease in Older Men With Differing Comorbid Disease Burdens.
    Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
    Urology; 2016 Jul; 93():68-76. PubMed ID: 27079130
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predicting prostate cancer progression: protocol for a retrospective cohort study to identify prognostic factors for prostate cancer outcomes using routine primary care data.
    Merriel SWD; May MT; Martin RM
    BMJ Open; 2018 Jan; 8(1):e019409. PubMed ID: 29391368
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The face of high risk prostate cancer.
    Albertsen PC
    World J Urol; 2008 Jun; 26(3):205-10. PubMed ID: 18401585
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Does comorbidity interact with prostate cancer to increase mortality? A Danish cohort study of 45 326 prostate cancer patients diagnosed during 1995-2011.
    Ording AG; Horváth-Puhó E; Lash TL; Ehrenstein V; Borre M; Vyberg M; Sørensen HT
    Acta Oncol; 2016 May; 55(5):611-8. PubMed ID: 26586474
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term survival in a Swedish population-based cohort of men with prostate cancer.
    Sandblom G; Dufmats M; Varenhorst E
    Urology; 2000 Sep; 56(3):442-7. PubMed ID: 10962312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.